KIN - キングスト―ン・カンパニ―ズ （Kindred Biosciences Inc.） キングスト―ン・カンパニ―ズKINのチャート
KINの企業情報
| symbol | KIN |
|---|---|
| 会社名 | Kingstone Companies Inc （キングスト―ン・カンパニ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 金融（Financials） |
| 概要 | 事業概要 キンドレッド・バイオサイエンス（Kindred Biosciences Inc.）は開発段階のバイオ医薬品会社である。同社はペット向け治療法の開発を中心とする。同社の製品パイプラインは犬、猫、および馬の適応症向けの小分子および生物製剤で構成される。同社は20以上の適応症の製品候補を開発し、小分子製品および生物製剤に焦点を当てる。同社はインターロイキン17A（IL-17a）、インターロイキン4A（IL-4Ra）、インターロイキン3（IL-3）、CD-20、免疫グロブリンE（IgE）、腫瘍壊死因子（TNF）などを標的とする抗体を開発する。同社の主力製品候補は馬にある発熱の治療に適応するジメタとネコの体重減少管理用KIND-010である。同社の他の製品候補には、KIND-010、KIND-014、KIND-015、KIND-510、KIND-502、KIND-0888、KIND-509およびアトピー性皮膚炎関連サイトカインを標的とする抗体が含まれる。 キングスト―ン・カンパニ―ズは、米国の保険持株会社。子会社を通じて、損害保険商品を提供。個人向けに住宅所有者保険、住居火災保険、3-4世帯住居保険、コンドミニアム保険、借家人保険、機械故障保険、アンブレラ保険を扱うほか、企業経営者向けの企業賠償責任保険や、軽車両の自動車保険、レンタカ―の車両保険などを提供する。 Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio. |
| 本社所在地 | 15 Joys Lane Kingston NY 12401 USA |
| 代表者氏名 | Richard H. Chin リチャード・H・チン |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-701-7901 |
| 設立年月日 | 22494 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2013年 |
| 従業員数 | 97人 |
| url | www.kingstonecompanies.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kin |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -39.30900 |
| 終値（lastsale） | 12.55 |
| 時価総額（marketcap） | 424186737 |
| 時価総額 | 時価総額（百万ドル） 435.34060 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 325.41060 |
| 当期純利益 | 当期純利益（百万ドル） -38.83200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Kindred Biosciences Inc revenues was not reported. Net loss increased 60% to $21.2M. Higher net loss reflects General and administrative -Gross increase from $4.2M to $8.6M (expense) Research and development - Gross increase of 51% to $10.3M (expense) Stock Based Compensation in General and increase of 19% to $2M (expense). |
KINのテクニカル分析
KINのニュース
Kindred Biosciences Inc Shares Close in on 52-Week High - Market Mover 2021/08/21 12:59:58 Kwhen Finance
Kindred Biosciences Inc (KIN) shares closed today at 0.5% below its 52 week high of $9.28, giving the company a market cap of $419M. The stock is currently up 114.2% year-to-date, up 125.1% over the past 12 months, and up 126.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.2%. Trading Activity Trading volume this week was 25.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.4% higher than its 20-day moving average, and 27.5% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 249.1% The company's stock price performance over the past 12 months beats the peer average by 165.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
DCF Advisers, LLC Buys VanEck Vectors Gold Miners ETF, Pfizer Inc, Kindred Biosciences Inc, ... 2021/08/16 22:38:25 GuruFocus
Related Stocks: PFE , GDX , KIN , PRTA , BABA , VIR , ALT , F , PSFE , DISCA , EQ , VIAC , FMS , CVS , LOW , TGT , MRVL , FGEN ,
Kindred Biosciences Inc Shares Close in on 52-Week High - Market Mover 2021/08/21 12:59:58 Kwhen Finance
Kindred Biosciences Inc (KIN) shares closed today at 0.5% below its 52 week high of $9.28, giving the company a market cap of $419M. The stock is currently up 114.2% year-to-date, up 125.1% over the past 12 months, and up 126.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.2%. Trading Activity Trading volume this week was 25.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.4% higher than its 20-day moving average, and 27.5% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 249.1% The company's stock price performance over the past 12 months beats the peer average by 165.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
DCF Advisers, LLC Buys VanEck Vectors Gold Miners ETF, Pfizer Inc, Kindred Biosciences Inc, ... 2021/08/16 22:38:25 GuruFocus
Related Stocks: PFE , GDX , KIN , PRTA , BABA , VIR , ALT , F , PSFE , DISCA , EQ , VIAC , FMS , CVS , LOW , TGT , MRVL , FGEN ,
Kindred Biosciences Inc Shares Close in on 52-Week High - Market Mover 2021/07/17 02:12:27 Kwhen Finance
Kindred Biosciences Inc (KIN) shares closed today at 100.0% below its 52 week high of $9.28, giving the company a market cap of $412M. The stock is currently up 111.6% year-to-date, up 119.2% over the past 12 months, and up 140.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 23.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 364.7% The company's stock price performance over the past 12 months beats the peer average by 240.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Kindred Biosciences Inc Shares Approach 52-Week High - Market Mover 2021/07/17 01:46:40 Kwhen Finance
Kindred Biosciences Inc (KIN) shares closed today at 100.0% below its 52 week high of $9.28, giving the company a market cap of $412M. The stock is currently up 111.6% year-to-date, up 119.2% over the past 12 months, and up 140.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 22.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 364.7% The company's stock price performance over the past 12 months beats the peer average by 240.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Kindred Biosciences Inc Shares Approach 52-Week High - Market Mover 2021/07/14 00:29:37 Kwhen Finance
Kindred Biosciences Inc (KIN) shares closed today at 0.9% below its 52 week high of $9.28, giving the company a market cap of $415M. The stock is currently up 113.0% year-to-date, up 136.0% over the past 12 months, and up 146.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.8%. Trading Activity Trading volume this week was 87.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 280.6% The company's stock price performance over the past 12 months beats the peer average by 194.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.